|
PRA-216 COPD Safety and Biomarker Study
RECRUITINGPhase 2Sponsored by Prana Therapies Inc
Actively Recruiting
PhasePhase 2
SponsorPrana Therapies Inc
Started2026-08-25
Est. completion2027-06-01
Eligibility
Age40 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07730281
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
Eligibility
Age: 40 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria: * Age 40-80 * Willing and able to attend all study visits, comply with study requirements. * Able and willing to provide written informed consent * Documented COPD diagnosis prior for at least 12 months prior to screening. * Currently receiving maintenance COPD medications at a stable dose for at least 3 months prior to visit 1 Exclusion Criteria: * Evidence of clinically significant pulmonary condition or disease other than COPD * Any physical or psychological condition that prohibits study completion * Known history of illicit drug use or alcoholism within 12 months prior to the first dose of study agent * History of severe allergic reactions or hypersensitivity * Major surgery occurring within 8 weeks months prior to first dose of investigational product. * Use of any marketed or investigational monoclonal or polyclonal antibody therapy within 4 months or 5 half-lives prior to visit 1.
Conditions2
COPDChronic Obstructive Pulmonary Disease (COPD)
Interventions1
Related trials
- Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma — Prana Therapies Inc
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorPrana Therapies Inc
Started2026-08-25
Est. completion2027-06-01
Eligibility
Age40 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07730281